DNER and hematologic disorder: Combined treatment with FHD-286 and other epigenetic drugs, such as decitabine, BET inhibitors, and menin inhibitors, has demonstrated synergistic effects in reducing AML burden without significant toxicity.741 Notably, FHD-286 has entered clinical development for treating various malignant tumors, including metastatic uveal melanoma (NCT04879017) and several malignant hematological disorders (NCT04891757).